Calcium channel blockers (CCBs) and angiotensin II receptor blockers (ARBs) may be associated with a reduced risk of dementia, according to a systematic review and network meta-analysis conducted by researchers from the Netherlands.
Use of the antipsychotic drug pimavanserin led to a substantial reduction in psychosis symptoms in individuals with dementia regardless of severity or subtype, according to the results of the HARMONY trial presented at AAIC 2020.
A new blood test for plasma P-tau217* accurately differentiates Alzheimer's disease (AD) from other neurodegenerative diseases — showing promise as a blood-based biomarker for early detection of AD, according to a study presented at the AAIC 2020 Meeting.
Risk factors for Alzheimer’s disease (AD) may be present as early as adolescence and young adulthood, data presented at AAIC 2020 have shown, highlighting the importance of addressing these factors early in the fight against AD and other dementias.
A new combination product (AXS-07), which consists of the triptan rizatriptan and the NSAID* meloxicam, led to rapid and sustained pain relief than treatment with either component alone or placebo in patients with a history of inadequate response to prior acute migraine treatment, according to data from the MOMENTUM study released during the AAN 2020 Meeting.
While aducanumab significantly reduced clinical decline in individuals with early Alzheimer's disease (AD) in one randomized trial, no changes were seen in another identical study — rendering the role of aducanumab in AD inconclusive.